Literature DB >> 20861921

Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.

M Suljagic1, L Laurenti, M Tarnani, M Alam, S N Malek, D G Efremov.   

Abstract

The PI3K/Akt pathway is activated in response to various microenvironmental stimuli that regulate the survival and proliferation of chronic lymphocytic leukemia (CLL) B-cells, including triggering of the B-cell receptor (BCR). Although this pathway is frequently targeted in cancer, no significant alterations have yet been identified in CLL. We now show that the phosphatase PH domain leucin-rich repeat protein phosphatase (PHLPP1), a recently identified tumor suppressor and negative regulator of the Akt kinase, is absent or expressed at substantially reduced levels in CLL B-cells. To determine what the consequences of PHLPP1 loss on BCR signaling are, we downregulated or re-expressed PHLPP1 in lymphoma cell lines and primary CLL B-cells, respectively. Downregulation of PHLPP1 increased BCR-induced phosphorylation and activation of the Akt, GSK3 and ERK kinases, whereas re-expression had the opposite effect. Importantly, re-expression of PHLPP1 in primary CLL cells prevented upregulation of Mcl-1 and inhibited the increase in leukemic cell viability induced by sustained BCR engagement. Enforced expression of PHLPP1 also affected the response to other microenvironmental stimuli, particularly in terms of ERK phosphorylation. Collectively, these data show that CLL cells lack an important negative regulator of the Akt and ERK pathways, which could confer them a growth advantage by facilitating the propagation of crucial microenvironment-derived stimuli.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861921     DOI: 10.1038/leu.2010.201

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

1.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

2.  Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.

Authors:  Roberto Negro; Stefania Gobessi; Pablo G Longo; Yantao He; Zhong-Yin Zhang; Luca Laurenti; Dimitar G Efremov
Journal:  Blood       Date:  2012-05-08       Impact factor: 22.113

3.  Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells.

Authors:  J A Mason; C A Davison-Versagli; A K Leliaert; D J Pape; C McCallister; J Zuo; S M Durbin; C L Buchheit; S Zhang; Z T Schafer
Journal:  Cell Death Differ       Date:  2016-02-26       Impact factor: 15.828

Review 4.  PHLPP Signaling in Immune Cells.

Authors:  Gema Lordén; Avery J Lam; Megan K Levings; Alexandra C Newton
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

Review 5.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

6.  Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL).

Authors:  M O'Hayre; M Niederst; J F Fecteau; V M Nguyen; T J Kipps; D Messmer; A C Newton; T M Handel
Journal:  Leukemia       Date:  2012-01-12       Impact factor: 11.528

7.  "Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''.

Authors:  P Oppezzo; G Dighiero
Journal:  Blood Cancer J       Date:  2013-09-20       Impact factor: 11.037

8.  Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells.

Authors:  Elena Tibaldi; Mario Angelo Pagano; Federica Frezzato; Valentina Trimarco; Monica Facco; Giuseppe Zagotto; Giovanni Ribaudo; Valeria Pavan; Luciana Bordin; Andrea Visentin; Francesca Zonta; Gianpietro Semenzato; Anna Maria Brunati; Livio Trentin
Journal:  Haematologica       Date:  2017-06-15       Impact factor: 9.941

9.  Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.

Authors:  Dimitar G Efremov; Adrian Wiestner; Luca Laurenti
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-10-09       Impact factor: 2.576

Review 10.  Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets.

Authors:  Giacomo Andreani; Giovanna Carrà; Marcello Francesco Lingua; Beatrice Maffeo; Mara Brancaccio; Riccardo Taulli; Alessandro Morotti
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.